VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer
- 1 January 1994
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 30 (3) , 299-303
- https://doi.org/10.1016/0959-8049(94)90245-3
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.Journal of Clinical Oncology, 1992
- Ifosfamide/MesnaDrugs, 1991
- Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.Journal of Clinical Oncology, 1990
- Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchusBritish Journal of Cancer, 1989
- Superiority of Alternating Non-Cross-Resistant Chemotherapy in Extensive Small Cell Lung CancerAnnals of Internal Medicine, 1987
- Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomasEuropean Journal of Cancer and Clinical Oncology, 1987
- VP-16 and cisplatin as first-line therapy for small-cell lung cancer.Journal of Clinical Oncology, 1985
- Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.Journal of Clinical Oncology, 1985
- PREVENTION OF ISOPHOSPHAMIDE-INDUCED UROTHELIAL TOXICITY WITH 2-MERCAPTOETHANE SULPHONATE SODIUM (MESNUM) IN PATIENTS WITH ADVANCED CARCINOMAThe Lancet, 1980
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958